The effects of A771726, the active metabolite of leflunomide, on experimental rat corneal neovascularization （NV） in vivo and on cultured human umbilical vein endothelial cells in vitro were studied. The corneal NV ...The effects of A771726, the active metabolite of leflunomide, on experimental rat corneal neovascularization （NV） in vivo and on cultured human umbilical vein endothelial cells in vitro were studied. The corneal NV was induced by alkali burn in 40 SD rats. The rats were randomly divided into 4 groups with 10 rats in each group. Group A was treated with 0.9% sodium chloride （control group）, and group B, group C and group D were given different concentrations of A771726 eye drops （0.5%, 1.0%, 2.0% respectively） 4 times daily during days 0--28. The occurrence and development of corneal NV were observed at 4, 7, 14, 21 and 28 day after alkali burn by a slit lamp microscope. The cultured human umbilical vein endothelial cells （ECV-304） were incubated with A771726 solution at different concentrations （20, 40, 80, 160, 320 μmol/L） for 36 h. The proliferation of cells was assessed by methyl thiazolyl tetrazolium （MTT）, and the expression of proliferating cell nuclear antigen （PCNA） in cells was detected by using immunofluorescence under the laser confocal microscope. The rat model showed that the onset of corneal NV was delayed and progression of corneal NV was inhibited in the groups C and D. The corneal NV areas in groups C and D were significantly smaller than in groups A and B （P〈0.01）. No significant difference was found in corneal NV areas between groups C and group D （P〉0.05）. A771726 solution （940 μmol/L） could inhibit proliferation of human umbilical vein endothelial cells and decrease the expression of PCNA in cells significantly, A771726, as the active metabolite of leflunomide, strongly prevented corneal NV induced by alkali burn in the in vivo model, and inhibited proliferation of human umbilical vein endothelial cells in the in vitro model. Therefore, A771726 may serve as an angiogenic inhibitor in the treatment of corneal NV.展开更多
目的:探讨来氟米特活性代谢产物A771726对类风湿关节炎(RA)患者外周血Th17细胞的影响及意义。方法:取RA患者外周血单个核细胞(PBMC),采用免疫磁珠法阴选出CD4+T辅助细胞(helper T cell,Th),将CD4+T细胞分别与不同剂量的A771726(15、30...目的:探讨来氟米特活性代谢产物A771726对类风湿关节炎(RA)患者外周血Th17细胞的影响及意义。方法:取RA患者外周血单个核细胞(PBMC),采用免疫磁珠法阴选出CD4+T辅助细胞(helper T cell,Th),将CD4+T细胞分别与不同剂量的A771726(15、30、60μg/ml)和地塞米松(10-6、10-7、10-8mol/L)共培养48 h,流式细胞术(FCM)检测RA患者外周血Th17/Th百分比;应用实时荧光定量逆转录聚合酶链技术(即RT-PCR)检测IL-17、ROR-γt mRNA水平。结果:在体外,来氟米特对RA患者外周血CD4+T细胞胞内IL-17、ROR-γt mRNA表达无明显抑制作用,地塞米松可以使CD4+T细胞胞内IL-17、ROR-γt mRNA表达明显减少,随着药物浓度的增加抑制作用更加明显。来氟米特对Th17/Th无明显影响,地塞米松能降低Th17/Th细胞百分比。结论:来氟米特对RA患者外周血Th17细胞无明显影响作用,而地塞米松则可显著降低Th17细胞在Th细胞中的比例。展开更多
文摘The effects of A771726, the active metabolite of leflunomide, on experimental rat corneal neovascularization （NV） in vivo and on cultured human umbilical vein endothelial cells in vitro were studied. The corneal NV was induced by alkali burn in 40 SD rats. The rats were randomly divided into 4 groups with 10 rats in each group. Group A was treated with 0.9% sodium chloride （control group）, and group B, group C and group D were given different concentrations of A771726 eye drops （0.5%, 1.0%, 2.0% respectively） 4 times daily during days 0--28. The occurrence and development of corneal NV were observed at 4, 7, 14, 21 and 28 day after alkali burn by a slit lamp microscope. The cultured human umbilical vein endothelial cells （ECV-304） were incubated with A771726 solution at different concentrations （20, 40, 80, 160, 320 μmol/L） for 36 h. The proliferation of cells was assessed by methyl thiazolyl tetrazolium （MTT）, and the expression of proliferating cell nuclear antigen （PCNA） in cells was detected by using immunofluorescence under the laser confocal microscope. The rat model showed that the onset of corneal NV was delayed and progression of corneal NV was inhibited in the groups C and D. The corneal NV areas in groups C and D were significantly smaller than in groups A and B （P〈0.01）. No significant difference was found in corneal NV areas between groups C and group D （P〉0.05）. A771726 solution （940 μmol/L） could inhibit proliferation of human umbilical vein endothelial cells and decrease the expression of PCNA in cells significantly, A771726, as the active metabolite of leflunomide, strongly prevented corneal NV induced by alkali burn in the in vivo model, and inhibited proliferation of human umbilical vein endothelial cells in the in vitro model. Therefore, A771726 may serve as an angiogenic inhibitor in the treatment of corneal NV.
